Trial Profile
A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CheckMate 915
- Sponsors Bristol-Myers Squibb
- 06 Jun 2023 Results comparing pre-treatment sera autoAb from URM melanoma patients (n=35) to NHW patients (n= 185) enrolled in Checkmate-238 (NCT02388906), Checkmate-915 (NCT03068455) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 Sep 2022 Results published in the Journal of Clinical Oncology
- 15 Sep 2022 Results of a pooled analysis of data from Checkmate 238 and CheckMate 915 studies assessed whether baseline serum autoantibody (autoAb) signatures predicted recurrence and severe toxicity in patients treated with adjuvant nivolumab, ipilimumab, or ipilimumab plus nivolumab published in the Clinical Cancer Research